Adnexus Therapeutics Overview

  • Founded
  • 2002

  • Status
  • Acquired/​Merged

  • Employees
  • 58

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $489M

Adnexus Therapeutics General Information


Developer of Adnectins biologics/medicines in the United States. The company's product candidates include Angiocept/CT-322, an anti-angiogenesis agent for treating cancer that blocks the VEGFR-2 pathway; and other Adnectin therapies for the treatment of oncology, immunology, and cardiovascular diseases.

Contact Information

Formerly Known As
Compound Therapeutics
Ownership Status
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Drug Discovery
Primary Office
  • 100 Beaver Street
  • Waltham, MA 02453
  • United States
+1 (781) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Adnexus Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 01-Oct-2007 $489M 000.00 00000 Completed Startup
6. IPO 21-Aug-2007 000.00 Cancelled Clinical Trials - Phase 2
5. Early Stage VC 07-Aug-2007 000.00 000.00 Completed Startup
4. Early Stage VC (Series B) 20-Jun-2006 0000 000.00 Completed Startup
3. Convertible Debt 24-May-2006 00.00 000.00 Completed Startup
2. Early Stage VC 28-Dec-2004 $15.6M $22.1M Completed Startup
1. Early Stage VC (Series A) 03-Apr-2003 $6.5M $6.5M Completed Startup
To view Adnexus Therapeutics’s complete valuation and funding history, request access »

Adnexus Therapeutics Executive Team (8)

Name Title Board Seat Contact Info
Bruce Silver MD Medical Director
You’re viewing 1 of 8 executive team members. Get the full list »

Adnexus Therapeutics Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Adnexus Therapeutics Former Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Applied Genomic Technology Capital Fund Venture Capital Minority 000 0000 000000 0
Atlas Venture Venture Capital Minority 000 0000 000000 0
Flagship Pioneering Venture Capital Minority 000 0000 000000 0
HBM Healthcare Investments Venture Capital Minority 000 0000 000000 0
HBM Partners Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »